Danish biotech (Nasdaq: GMAB) on Saturday revealed that US pharma major (AbbVie (NYSE: ABBV) has filed a complaint in the US ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

As previously reported, Erste Group upgraded AbbVie (ABBV) to Buy from Hold. The firm notes AbbVie recently confirmed its ...

Company Announcement <li /> AbbVie Inc. files complaint against Genmab in the U.S. District Court for the W ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

AbbVie has not pursued any development of products incorporating their alleged trade secrets. Genmab categorically refutes these allegations and will vigorously defend the company against AbbVie ...

We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look ...

On Monday, Erste Group upgraded AbbVie stock (NYSE:ABBV) from Hold to Buy, citing the pharmaceutical company’s robust sales growth forecast and promising pipeline of new products. With a ...

Forget the old adage “it takes money to make money.” In the stock market, even a measly $500 can kickstart a fortune. Time, not a fat wallet, is the real MVP here. With the right picks, that modest ...

Drugmakers are urging the Trump administration and European Union officials to exclude medical goods from expanding tariff ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...